|
시장보고서
상품코드
2055270
종양 혈액 검사 시장 : 바이오마커 유형별, 기술별, 임상 용도별, 암 유형별, 최종사용자별, 지역별Tumor Blood Testing Market, By Biomarker Type, By Technology, By Clinical Application, By Cancer Type, By End User, By Geography |
||||||
종양 혈액 검사 시장은 2026년 106억 9,000만 달러로 추정되며, 2033년까지 275억 9,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 14.5%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 106억 9,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 14.50% | 2033년 시장 규모 예측 : | 275억 9,000만 달러 |
세계 종양 혈액 검사 시장은 광범위한 종양 진단 분야에서 혁신을 주도하는 분야로, 현대 의료에서 암의 검출, 모니터링 및 치료 방침 결정에 대한 접근 방식을 근본적으로 재편하고 있습니다.
액체 생검으로도 알려진 종양 혈액 검사는 말초 혈액 샘플 내에 존재하는 순환 종양 세포(CTC), 순환 종양 DNA(ctDNA), 엑소좀 및 기타 종양 유래 바이오마커를 분석하는 획기적인 비침습적 진단 기술들을 포괄합니다.
이 혁신적인 접근 방식은 기존의 조직 생검에 비해 환자의 불편함을 줄이고, 시술에 따른 위험을 낮추며, 실시간 모니터링을 가능하게 하고, 종양의 이질성을 보다 종합적으로 파악할 수 있는 등 큰 이점을 제공합니다. 이 시장은 암의 조기 검진 및 진단부터 치료법 선택, 치료 모니터링, 미세 잔류 병변의 검출에 이르기까지 광범위한 용도를 아우르고 있습니다.
유전체 시퀀싱 기술의 발전, 인공지능(AI)의 통합, 그리고 액체 생검의 유효성을 뒷받침하는 임상적 근거 증가에 힘입어, 종양 혈액 검사 시장은 전례 없는 성장세를 보이고 있습니다. 전 세계 암 유병률 증가와 더불어, 정밀의학(Precision Medicine) 접근법 및 맞춤형 치료 전략에 대한 수요가 높아지면서, 전 세계 다양한 의료 현장에서 시장 확대가 지속적으로 추진되고 있습니다.
시장 역학
세계 종양 혈액 검사 시장은 급속한 성장과 임상 현장에서의 도입을 뒷받침하는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 주요 성장 요인은 전 세계 암 부담 증가에 있습니다. 발병률 증가에 따라, 치료 전 과정에 걸쳐 조기 발견과 지속적인 모니터링을 가능하게 하는 보다 효율적이고 사용하기 쉬우며 환자 친화적인 진단 솔루션이 요구되고 있습니다.
차세대 염기서열 분석, 디지털 PCR 및 분자 프로파일링 기술의 발전으로 인해, 액체 생검의 민감도와 특이도가 크게 향상되어, 침습적인 조직 채취 절차를 대체할 현실적인 대안으로 점점 더 주목받고 있습니다. 정밀의료와 맞춤형 치료 접근법에 대한 관심이 높아지고 있는 점도 시장 성장을 더욱 가속화하고 있습니다. 종양 혈액 검사를 통해 치료 반응, 내성 기전, 질병의 진행 상황을 그 어느 때보다 정밀하게 실시간으로 모니터링할 수 있게 되기 때문입니다. 그러나 시장에는 첨단 검사 플랫폼에 따른 높은 비용, 많은 지역에서 보험 적용 범위가 제한적이라는 점, 그리고 새로운 진단 기술을 둘러싼 규제상의 복잡성 등 뚜렷한 제약 요인이 존재합니다.
또한, 의료 시스템 간에 표준화된 프로토콜, 품질 관리 조치 및 임상 지침이 부재한 것은 도입 과정에서 어려움을 초래하고 보급을 저해할 수 있습니다. 이러한 제약이 있음에도 불구하고, 조기 암 검진 프로그램으로의 적용 확대, 진단 정확도 향상을 위한 인공지능(AI) 및 머신러닝 플랫폼과의 통합, 그리고 연구 개발 활동에 대한 투자 확대를 통해 큰 기회가 창출되고 있습니다. 제약 회사, 진단 기기 제조업체, 의료 기관 간의 협력이 강화되고 있는 것은 시장 확대를 위한 큰 가능성을 보여주고 있습니다. 특히, 기존의 생검 인프라가 여전히 제한적인 반면, 암 진단에 대한 수요가 비약적으로 증가하고 있는 신흥국에서 그 가능성은 매우 큽니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 종양 혈액 검사 시장의 주요 업체들을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 종양 혈액 검사 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 종양 혈액 검사 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 종양 혈액 검사 시장 : 바이오마커 유형별, 2021년-2033년
제5장 세계의 종양 혈액 검사 시장 : 기술별, 2021년-2033년
제6장 세계의 종양 혈액 검사 시장 : 임상 용도별, 2021년-2033년
제7장 세계의 종양 혈액 검사 시장 : 암 유형별, 2021년-2033년
제8장 세계의 종양 혈액 검사 시장 : 최종사용자별, 2021년-2033년
제9장 세계의 종양 혈액 검사 시장 : 지역별, 2021년-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
LSHTumor Blood Testing Market is estimated to be valued at USD 10.69 Bn in 2026 and is expected to reach USD 27.59 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.69 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 14.50% | 2033 Value Projection: | USD 27.59 Bn |
The global tumor blood testing market represents a transformative segment within the broader oncology diagnostics landscape, fundamentally reshaping how cancer detection, monitoring, and treatment decisions are approached in modern healthcare.
Tumor blood testing, also known as liquid biopsy, encompasses a revolutionary array of non-invasive diagnostic techniques that analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other tumor-derived biomarkers present in peripheral blood samples.
This innovative approach offers significant advantages over traditional tissue-based biopsies, including reduced patient discomfort, lower procedural risks, real-time monitoring capabilities, and the ability to capture tumor heterogeneity more comprehensively. The market encompasses various applications ranging from early cancer screening and diagnosis to treatment selection, therapeutic monitoring, and minimal residual disease detection.
With advancing genomic sequencing technologies, artificial intelligence integration, and growing clinical evidence supporting liquid biopsy efficacy, the tumor blood testing market is experiencing unprecedented growth momentum. The increasing prevalence of cancer globally, coupled with rising demand for precision medicine approaches and personalized treatment strategies, continues to drive market expansion across diverse healthcare settings worldwide.
Market Dynamics
The global tumor blood testing market is propelled by several compelling drivers that underscore its rapid expansion and clinical adoption. The primary growth driver stems from the increasing global cancer burden, with rising incidence rates necessitating more efficient, accessible, and patient-friendly diagnostic solutions that can facilitate early detection and continuous monitoring throughout treatment journeys.
Technological advancements in next-generation sequencing, digital PCR, and molecular profiling techniques have significantly enhanced the sensitivity and specificity of liquid biopsies, making them increasingly viable alternatives to invasive tissue sampling procedures. The growing emphasis on precision medicine and personalized treatment approaches further accelerates market growth, as tumor blood testing enables real-time monitoring of treatment response, resistance mechanisms, and disease progression with unprecedented accuracy. However, the market faces notable restraints including high costs associated with advanced testing platforms, limited reimbursement coverage in many regions, and regulatory complexities surrounding novel diagnostic technologies.
Additionally, the lack of standardized protocols, quality control measures, and clinical guidelines across different healthcare systems creates implementation challenges that may hinder widespread adoption. Despite these constraints, substantial opportunities emerge through expanding applications in early-stage cancer screening programs, integration with artificial intelligence and machine learning platforms for enhanced diagnostic accuracy, and growing investments in research and development activities. The increasing collaboration between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions presents significant potential for market expansion, particularly in emerging economies where traditional biopsy infrastructure remains limited but demand for cancer diagnostics continues to grow exponentially.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tumor blood testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Illumina, Inc., Guardant Health, Bio-Rad Laboratories, Abbott Laboratories, Qiagen, Agilent Technologies, Thermo Fisher Scientific, Siemens Healthineers, GE Healthcare, BD (Becton, Dickinson and Company), PerkinElmer, Myriad Genetics, Sysmex Corporation, and Danaher Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tumor blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor blood testing market
Market Segmentation
- Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs) / Exosomes
- Other Cell-Free Nucleic Acids
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- Polymerase Chain Reaction (PCR)-Based Testing
- Next-Generation Sequencing (NGS)
- Microarray-Based Testing
- Mass Spectrometry
- Immunoassays
- Clinical Application Insights (Revenue, USD Bn, 2021 - 2033)
- Early Detection/Cancer Screening
- Diagnosis
- Therapy Selection
- Treatment Monitoring
- Minimal Residual Disease (MRD) Detection
- Recurrence Monitoring/Prognosis
- Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Guardant Health
- Bio-Rad Laboratories
- Abbott Laboratories
- Qiagen
- Agilent Technologies
- Thermo Fisher Scientific
- Siemens Healthineers
- GE Healthcare
- BD (Becton, Dickinson and Company)
- PerkinElmer
- Myriad Genetics
- Sysmex Corporation
- Danaher Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tumor Blood Testing Market, By Biomarker Type
- Global Tumor Blood Testing Market, By Technology
- Global Tumor Blood Testing Market, By Clinical Application
- Global Tumor Blood Testing Market, By Cancer Type
- Global Tumor Blood Testing Market, By End User
- Global Tumor Blood Testing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tumor Blood Testing Market, By Biomarker Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Circulating Tumor DNA (ctDNA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Circulating Tumor Cells (CTCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Extracellular Vesicles (EVs) / Exosomes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Cell-Free Nucleic Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Tumor Blood Testing Market, By Technology, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Polymerase Chain Reaction (PCR)-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Microarray-Based Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mass Spectrometry
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Immunoassays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Tumor Blood Testing Market, By Clinical Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Early Detection/Cancer Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Minimal Residual Disease (MRD) Detection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Recurrence Monitoring/Prognosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Tumor Blood Testing Market, By Cancer Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Tumor Blood Testing Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Tumor Blood Testing Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Clinical Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Qiagen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GE Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BD (Becton, Dickinson and Company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PerkinElmer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sysmex Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
